Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy.

Judge DP, Kass DA, Thompson WR, Wagner KR.

Am J Cardiovasc Drugs. 2011 Oct 1;11(5):287-94. doi: 10.2165/11594070-000000000-00000. Review.

PMID:
21812510
2.

Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.

Ogata H, Ishikawa Y, Ishikawa Y, Minami R.

J Cardiol. 2009 Feb;53(1):72-8. doi: 10.1016/j.jjcc.2008.08.013. Erratum in: J Cardiol. 2009 Apr;53(2):316.

3.

Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy.

Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA.

Circulation. 2005 Nov 1;112(18):2799-804.

4.

Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers.

Mosqueira M, Zeiger U, Förderer M, Brinkmeier H, Fink RH.

Med Res Rev. 2013 Sep;33(5):1174-213. doi: 10.1002/med.21279. Review.

PMID:
23633235
5.

Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.

Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD.

Am J Cardiol. 2012 Jul 1;110(1):98-102. doi: 10.1016/j.amjcard.2012.02.064.

PMID:
22463839
6.

The heart in human dystrophinopathies.

Finsterer J, Stöllberger C.

Cardiology. 2003;99(1):1-19. Review.

PMID:
12589117
7.

Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy.

Su JB, Cazorla O, Blot S, Blanchard-Gutton N, Ait Mou Y, Barthélémy I, Sambin L, Sampedrano CC, Gouni V, Unterfinger Y, Aguilar P, Thibaud JL, Bizé A, Pouchelon JL, Dabiré H, Ghaleh B, Berdeaux A, Chetboul V, Lacampagne A, Hittinger L.

Cardiovasc Res. 2012 Jul 1;95(1):86-96. doi: 10.1093/cvr/cvs161.

PMID:
22562664
9.

Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy.

Su JA, Ramos-Platt L, Menteer J.

Pediatr Cardiol. 2016 Apr;37(4):678-85. doi: 10.1007/s00246-015-1331-1.

PMID:
26714815
10.

[Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure].

Matsumura T, Saito T, Miyai I, Nozaki S, Kang J.

Rinsho Shinkeigaku. 1999 Jun;39(6):643-8. Japanese.

PMID:
10502990
11.

[Management of myocardial damage in muscular dystrophy].

Tamura T.

Brain Nerve. 2011 Nov;63(11):1217-28. Review. Japanese.

PMID:
22068474
12.
13.

Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.

Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, Scott WA.

Am J Cardiol. 2006 Sep 15;98(6):825-7.

PMID:
16950195
14.

Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach.

Townsend D, Yasuda S, Metzger J.

Expert Rev Cardiovasc Ther. 2007 Jan;5(1):99-109. Review.

PMID:
17187461
15.

[A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy].

Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S.

Rinsho Shinkeigaku. 2011 Oct;51(10):743-50. Japanese.

PMID:
22019865
16.

Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy.

Chu V, Otero JM, Lopez O, Sullivan MF, Morgan JP, Amende I, Hampton TG.

Muscle Nerve. 2002 Oct;26(4):513-9.

PMID:
12362417
17.

Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.

Fayssoil A, Nardi O, Orlikowski D, Annane D.

Heart Fail Rev. 2010 Jan;15(1):103-7. doi: 10.1007/s10741-009-9156-8. Review.

PMID:
19943106
18.

Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging.

Ashford MW Jr, Liu W, Lin SJ, Abraszewski P, Caruthers SD, Connolly AM, Yu X, Wickline SA.

Circulation. 2005 Oct 18;112(16):2462-7.

19.

Congestive heart failure: what should be the initial therapy and why?

Chatterjee K.

Am J Cardiovasc Drugs. 2002;2(1):1-6. Review.

PMID:
14727993
20.

Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy.

Schade van Westrum SM, Hoogerwaard EM, Dekker L, Standaar TS, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, van Essen AJ, Leschot NJ, Wilde AA, de Haan RJ, de Visser M, van der Kooi AJ.

Neurology. 2011 Jul 5;77(1):62-6. doi: 10.1212/WNL.0b013e318221ad14.

PMID:
21700587
Items per page

Supplemental Content

Support Center